Iveric bio, inc. (OPHT)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating Activities
Net Income (Loss) Attributable to Parent

-15,076

-17,478

-14,437

-14,443

-12,501

104,114

-14,745

-13,209

-13,073

-9,542

189,073

-22,204

-43,122

-66,283

-60,891

-29,945

-36,301

-35,649

-39,573

-37,131

6,636

-

-

-72,990

-20,682

Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and other expense

38

39

40

40

43

44

45

44

50

821

586

585

808

261

187

174

178

163

76

403

56

47

37

31

12

Amortization of premium and discounts on investment securities

-

-

-

-

-

-

-

-

-

0

-3

-39

-98

-141

-123

-135

-196

-329

-449

-1,077

-991

-

-

-

-

Deferred income taxes

-

-

-

-

-

-233

0

0

233

-3,529

171

-8

0

38

63

-260

23,113

-

-

-

-

-

-

-

-

Share-based compensation

2,324

2,377

2,126

2,207

2,470

2,724

2,604

2,662

3,082

3,708

3,411

4,988

6,064

6,771

8,248

8,309

8,332

6,286

7,041

6,379

5,054

3,548

3,580

3,183

2,729

Changes in operating assets and liabilities:
Due from Novartis Pharma AG

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-30,191

20,135

5,673

4,389

-247

-50,002

49,289

-

-

-

-

Income tax receivable

2,942

-130

-1,636

1

0

0

0

0

-1,387

1,335

0

0

52

-24,265

-19

-2,213

23,076

-

-

-

-

-

-

-

-

Prepaid expense and other assets

-

-

-

-

-

-

-

-917

-310

1,324

-1,302

-1,912

1,520

1,564

-382

-403

216

11

-5,344

1,985

88

-

-

-

-

Prepaid expense and other assets

140

-

-

-

306

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,535

Accrued interest receivable

-

-

-

-

-

-

-

-

-

-1

-190

-201

-74

-46

-10

-147

0

165

111

-878

447

-

-

-

-

Other assets

-

-

-

-

-

-

-

-9

16

-

-19

43

-459

-8

-22

-8

11

172

-17

-27

-21

-

-

-

-

Accrued research and development expenses

1,524

1,910

-2,695

1,735

-1,427

1,421

779

-59

212

-1,228

-6,475

-15,268

-19,285

7,223

14,866

3,424

2,907

-1,260

10,305

1,672

185

1,576

4,559

-1,019

317

Accounts payable and accrued expenses

-3,254

1,962

425

254

-2,882

1,255

620

716

-4,273

-344

1,627

-2,389

-3,375

1,643

2,620

482

-4,731

4,168

1,700

393

-2,950

2,001

2,667

286

-57

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-1,662

-1,661

-

-1,662

1,822

-1,458

-1,644

-1,638

-1,598

8,322

-

-

-

-

Net cash used in operating activities

-17,526

-11,909

-12,228

-9,750

-14,603

-10,082

-10,821

-8,920

-12,088

-13,245

-16,072

-30,992

-61,512

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-36,740

-

-23,820

15,834

-31,509

10,767

-44,627

161,094

-16,146

Investing Activities
Purchase of marketable securities

-

-

-

-

-

-

-

-

-

0

0

0

12,014

24,074

36,120

-2

12,005

28,644

161,003

77,485

144,433

212,359

140,579

20,577

224,247

Maturities of marketable securities

-

-

-

-

-

-

-

-

-

0

55,347

79,340

32,119

24,000

12,000

40,500

10,000

0

35,000

57,000

174,000

-

-

-

-

Purchase of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

325

98

87

62

1,039

857

655

64

313

500

114

728

Net cash provided by (used in) investing activities

0

0

150

0

0

0

0

0

0

0

55,347

79,340

20,105

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,067

-

240,183

-21,134

29,503

-111,072

-111,079

19,309

-224,975

Financing Activities
Proceeds from employee stock plan purchases

179

192

40

0

41

0

38

0

27

0

25

15

31

-

-

-

-

5,449

1,812

2,452

1,760

1,728

921

289

11

Proceeds from follow-on public offering, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

55,409

Proceeds from stock option/employee stock purchase plan exercises

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,590

3,040

768

-

-

-

-

-

-

-

-

Net cash provided by financing activities

179

42,757

40

0

41

6,075

38

0

27

0

25

15

31

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash and cash equivalents

-17,347

30,848

-12,038

-9,750

-14,562

-4,007

-10,783

-8,920

-12,061

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

39,300

48,363

-41,376

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from royalty purchase agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

41,666

0

0

41,667

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

768

-

1,812

2,452

1,760

45,315

2,012

1,533

97,087

Net change in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-38,039

-

218,175

-2,848

-246

-54,990

-153,694

181,936

-144,034

Supplemental disclosure of cash paid
Income taxes received, net

-

-

-

-

-

-4,934

0

3,892

-1,425

-245

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosures of non-cash information related to investing activities
Change in unrealized loss on available for sale securities, net of tax

-

-

-

-

-

-

-

-

-

-

-

36

-10

-

-41

-122

477

-552

55

41

48

-100

10

7

18